Curetis Announces Change of the Composition of Its Supervisory Board
- Dr. Holger Reithinger resigns as member of the Supervisory Board
- Company exploring options to further evolve Board at upcoming 2018 AGM
Amsterdam, the Netherlands; San Diego, CA, USA; and Holzgerlingen, Germany; 30 April 2018; published at 01:30 EDT -- Curetis N.V. (the "Company" and, together with Curetis GmbH and Curetis USA Inc., "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that Dr. Holger Reithinger, General Partner at Forbion, resigns from Curetis' Supervisory Board effective today, April 30, 2018.
Dr. Reithinger has served on the Supervisory Board of Curetis N.V. since the IPO in November 2015. Previously, he had already served on the Supervisory Board of the predecessor company, Curetis AG, to which he had been elected in 2011 to represent Forbion, one of the first venture capital companies that invested in Curetis. Following the recent PIPE financing, Forbion currently holds about 8.7% of Curetis' share capital.
After Dr. Reithinger's resignation, the Supervisory Board consists of six members: William E. Rhodes, III. (Chairman of the Supervisory Board), Mario Crovetto, Dr. Werner Schaefer, Dr. Prabha Fernandes, Dr. Rudy DeKeyser, and Dr. med. Nils Clausnitzer who had been elected at the last AGM in 2017 to further strengthen the Supervisory Board.
"Holger has been a very engaged Supervisory Board colleague who very actively supported the Company with his broad network in the industry. On behalf of the Supervisory Board, I would like to thank Holger for his many years of strong support and dedication to the Company," commented William E. Rhodes, Chairman of the Curetis N.V. Supervisory Board. "While we believe that with the remaining six members the Supervisory Board is still very balanced, the Board is also exploring options to use Holger's resignation as an opportunity to further evolve the composition of the Board at the upcoming 2018 Annual General Shareholder Meeting."
"On behalf of the entire Curetis Management Team, I would like to sincerely thank Holger for his invaluable support and continuous guidance and advice over many years, which has helped develop Curetis from a small, R&D-driven company to a publicly listed, fully integrated, commercial-stage molecular diagnostics enterprise with a global presence," said Oliver Schacht, PhD, CEO of Curetis N.V.
###
About Curetis
Curetis N.V.'s (Euronext: CURE) goal is to become a leading provider of innovative solutions for molecular microbiology diagnostics designed to address the global challenge of diagnosing severe infectious diseases and identifying antibiotic resistances in hospitalized patients.
Curetis' Unyvero System is a versatile, fast and highly automated molecular diagnostic platform for easy-to-use, cartridge-based solutions for the comprehensive and rapid detection of pathogens and antimicrobial resistance markers in a range of severe infectious disease indications. Results are available within hours, a process that can take days or even weeks if performed with standard diagnostic procedures, and thereby facilitates improved patient outcomes, stringent antibiotic stewardship and health economic benefits. Unyvero in vitro diagnostic (IVD) products are marketed in Europe, the Middle East, Asia and the U.S.
Curetis' wholly owned subsidiary Ares Genetics GmbH offers next-generation solutions for infectious disease diagnostics and therapeutics. The ARES Technology Platform combines the world's most comprehensive database on the genetics of antimicrobial resistances, ARESdb, with advanced bioinformatics and artificial intelligence.
For further information, please visit www.curetis.com and www.ares-genetics.com.
Legal Disclaimer
This announcement contains inside information. This is a public announcement pursuant to article 17 paragraph 1 of the European Market Abuse Regulation (596/2014).
This document constitutes neither an offer to buy nor to subscribe for securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.
The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.
This press release includes statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will," or "should" and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis' actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
Curetis' Contact Details
Curetis GmbH
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr@curetis.com or ir@curetis.com
www.curetis.com
Curetis International Media & Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
Curetis U.S. Media & Investor Inquiries
The Ruth Group
Lee Roth
lroth@theruthgroup.com
Tel. +1 646 536 7012
